28 completed, 3 recruiting, 2 terminated, 2 unknown. 37 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 37 | Completed 28, Recruiting 3, Terminated 2, Unknown 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 8 | Completed 6, Recruiting 1, Terminated 1 |
Follow Inhalation: new trials by email Literature Review of Inhalation trials Research Report on Inhalation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa Rev-56 for Inhalation, Placebo: Normal saline - Healthy Participants, Non-cystic Fibrosis Bronchiectasis | Phase 1 | Active not recruiting | Revagenix, Inc. | 64 | 2026-07-13 | 2026-10-14 |
| A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD HRS-9821 Powder for Inhalation, Placebo - COPD | Phase 1 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 48 | 2026-07-09 | 2026-07-20 |
| A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects TQC3302 inhalation spray, TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation, Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray - Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. | 33 | 2025-11-25 | 2026-08-27 |
| A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 48 | 2025-02-11 | 2025-08-15 |
| A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 60 | 2024-05-22 | 2024-10-29 |
| Bioequivalence Study of Budesonide/Formoterol Inhalation Powder in Healthy Participants Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Test), Budesonide and Formoterol Fumarate Powder for Inhalation (II) (Reference) - Asthma, Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Completed | Shanghai Xin Huanghe Pharmaceutical Co., Ltd. | 30 | 2024-01-13 | 2026-09-04 |
| Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer CIS-DPI - NSCLC (advanced Non-small Cell Lung Cancer), Stage IV Lung Cancer | Phase 1 / Phase 2 | Recruiting | Inhatarget Therapeutics | 32 | 2023-06-23 | 2025-03-26 |
| Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis ABCI, Placebo - Cystic Fibrosis | Phase 1 | Recruiting | Cystetic Medicines, Inc. | 108 | 2023-03-21 | 2025-02-12 |
| A Study of FB2001 for Inhalation in Healthy Chinese Adults FB2001 for inhalation, FB2001 for inhalation placebo - COVID-19 Pandemic | Phase 1 | Completed | Frontier Biotechnologies Inc. | 32 | 2022-10-21 | 2023-01-11 |
| Inhaled Tobramycin in BPD Tobramycin solution for inhalation 78mg dose, Tobramycin solution for inhalation 150mg dose, Tobramycin solution for inhalation 216mg dose - Bronchopulmonary Dysplasia | Phase 1 | Completed | Erik Allen Jensen | 27 | 2022-03-22 | 2025-01-31 |
| Detection of Cannabis Impairment With ISBRG's SpotLight-THC Cannabis(THC) inhaled - Cannabis | Phase 1 | Unknown | ISBRG Corp | 75 | 2022-03-01 | 2022-03-11 |
| Study of Inhaled Epinephrine and Intramuscular Epinephrine Administered to Healthy Adults EpiPen ®., Epinephrine (0.3mg) inhaled, Epinephrine (1.3mg) - Anaphylactic Reaction | Phase 1 | Completed | De Motu Cordis | 23 | 2022-01-06 | 2023-07-24 |
| A Clinical Trial of TQC3721 Suspension for Inhalation TQC3721 suspension for inhalation, TQC3721 suspension placebo for inhalation - Chronic Obstructive Pulmonary Disease | Phase 1 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 114 | 2021-10-18 | 2021-10-25 |
| Treatment of U.S. Veterans With Mild Traumatic Brain Injury With Hyperbaric Oxygen Therapy Oxygen 100 % Gas for Inhalation, Hyperbaric Oxygen Therapy Chamber - Mild Traumatic Brain Injury, Hyperbaric Oxygen Therapy | Phase 1 | Completed | Nova Southeastern University | 40 | 2021-09-07 | 2025-08-26 |
| Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for Inhalation, Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), Placebo for Inhalation - COVID-19 | Phase 1 / Phase 2 | Completed | CanSino Biologics Inc. | 840 | 2021-04-21 | 2023-02-08 |
| Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients. AMOR 18 Powder & Inhalation, Placebo - Covid19 | Phase 1 / Phase 2 | Completed | Amorphical Ltd. | 66 | 2021-02-09 | 2024-02-28 |
| To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration AZD5634 for inhalation, AZD5634 for infusion, Placebo - Cystic Fibrosis | Phase 1 | Completed | AstraZeneca | 63 | 2016-02-11 | 2018-11-05 |
| A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects [14C]-GSK961081 solution for IV infusion, [14C]-GSK961081 oral solution, GSK961081 dry powder for inhalation - Pulmonary Disease, Chronic Obstructive | Phase 1 | Completed | Theravance Biopharma | 6 | 2016-02-08 | 2021-10-06 |
| Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication ADASUVE® - BiPolar | Phase 1 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 30 | 2014-07-01 | 2021-11-12 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345. GSK2339345 (Inhaled) Single Dose, Placebo (Inhaled) Single Dose, GSK2339345 (Inhaled) Repeat Dose - Cough | Phase 1 | Completed | GlaxoSmithKline | 36 | 2012-04-23 | 2017-07-26 |
Showing 20 of 37. Sign in to see all of them.
Cystic Fibrosis (8) · Pulmonary Disease, Chronic Obstructive (8) · Asthma (3) · COVID-19 (3) · Respiratory Aspiration (2) · Acidosis, Respiratory (1) · Alzheimer Disease 5 (1) · Anaphylaxis (1) · Brain Concussion (1) · Bronchial Spasm (1) · Bronchopulmonary Dysplasia (1) · Carcinoma, Non-Small-Cell Lung (1) · Cough (1) · Depression (1) · Driving Under the Influence (1)
Boehringer Ingelheim (5) · Amgen (3) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3) · Insmed Incorporated (2) · Mallinckrodt (2) · Amorphical Ltd. (1) · Amphastar Pharmaceuticals, Inc. (1) · AstraZeneca (1) · Boston Children's Hospital (1) · CanSino Biologics Inc. (1) · Case Western Reserve University (1) · Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. (1) · Cystetic Medicines, Inc. (1) · De Motu Cordis (1) · Erik Allen Jensen (1)
United States (15) · China (8) · United Kingdom (3) · Australia (2) · Belgium (2) · France (1) · Hungary (1) · Israel (1) · New Zealand (1) · North Macedonia (1) · Poland (1) · Serbia (1) · Slovakia (1) · Spain (1) · Ukraine (1)
Alison C Bested, MD FRCPC (1) · Dawn Ericson, MD (1) · Elliott C Dasenbrook, MD MHS (1) · Fengcai Zhu, MSD (1) · Gina Eagle, MD (1) · Martin Burke, MD, PhD (1) · Nicholas A Haglund, MD (1) · Peter O'Neill (1) · Ronald Goldwater, MDCM, M.Sc, CPI (1) · Scott Sagel, MD (1) · Thierry Berghmans, Prof.MD. (1)
PMID 19183804, PMID 28205038, PMID 30230263, PMID 32423275, PMID 35227647, PMID 37202147, PMID 38543926